• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Atara Biotherap (NQ: ATRA )

    7.440 +0.040 (+0.54%)
    Streaming Delayed Price Updated: 12:35 PM EDT, Sep 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 24,181
    Open 7.560
    Bid (Size) 7.410 (1)
    Ask (Size) 7.440 (1)
    Prev. Close 7.400
    Today's Range 7.310 - 7.560
    52wk Range 4.965 - 45.75
    Shares Outstanding 101,102,152
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
    From Atara Biotherapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    -37.99%
    -37.99%
    1 Month
    +5.83%
    +5.83%
    3 Month
    +1.99%
    +1.99%
    6 Month
    -57.49%
    -57.49%
    1 Year
    -81.04%
    -81.04%

    More News

    Read More
    Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings
    Via Benzinga
    Exposures Fossil Fuels
    Atara Biotherapeutics (ATRA) Stock Is Up 20%: What's Going On?
    Via Benzinga
    Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Atara Biotherapeutics Announces $36 Million Registered Direct Offering
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    ATRA Stock Earnings: Atara Biotherapeutics Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.